Conduct sampling, routine monitoring, and microbiological testing of water, raw materials, and finished products.
Perform environmental monitoring, microbial limit tests, endotoxin testing, and method validation.
Candidates should have experience in Formulation regulatory manufacturing company such as USFDA, MHRA and EU Exposure to regulatory audits like USFDA, MHRA and EU is mandatory. Centaur Pharmaceutical
Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received tentative approval from the United States Food and Drug Administration (USFDA) for Budesonide delayed-release capsules, 4 mg (USRLD: Tarpeyo Capsules, 4 mg).
The U.S. Food and Drug Administration (FDA) approved Kygevvi (doxecitine and doxribtimine) powder to treat thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients who start to show symptoms when they are 12 years old or younger. Kygevvi received Breakthrough Therapy Designation for this indication.
M.Sc / M.Tech. in any field related to life sciences. Candidate must be NET / GATE qualified. Experience in molecular biology and structural biology techniques including cloning, expression, purification of proteins will be preferred
PhD in any area of Life Sciences or Masters with minimum three years of experience. Candidate with first author publication in a reputed journal will be preferred.
First class in Masters Degree with specialization in Cancer Biology / Epigenetics / Molecular Biology / Cell Biology / Nanoscience and Nanotechnology from a recognized University with good knowledge of molecular biology.
Implement and maintain quality control procedures within the QMS framework. Conduct thorough inspections and tests on products and materials at various stages of production
Pfizer Inc. announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery. The lawsuit includes claims for breach of contract, breach of fiduciary duty, and tortious interference in contract arising from Metseras alleged breach of its obligations under the merger agreement between Pfizer and Metsera.
Semaglutide significantly reduced major adverse cardiovascular events in patients with overweight or obesity with cardiovascular disease but without diabetes, as per recent research study conducted by University College London.